OverviewSuggest Edit

Vical is a company that develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Its core technology provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy. The technology is based on plasmid DNA (pDNA), closed loops of DNA that encode any protein of interest. When injected into tissues such as skeletal muscle or the skin, cells take up pDNA and produce the encoded protein. This allows for pDNA to be used as the basis for a broad range of biopharmaceutical products: infectious disease vaccines, cancer vaccines or immunotherapeutics, and growth factors to stimulate angiogenesis and tissue repair in diseases such as cardiovascular disorders. The company merged with Brickell Biotech.
StateClosed
TypePublic
Founded1987
HQSan Diego, US
Websitevical.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2018)30(-59%)
Revenue (FY, 2019)$7.9 M(+389%)
Share Price (Nov 2019)$2.1 (+212%)
Cybersecurity ratingAMore

Vical Office Locations

Vical has an office in San Diego
San Diego, US (HQ)
10390 Pacific Center Ct
Show all (1)

Vical Financials and Metrics

Vical Revenue

Vical's revenue was reported to be $7.92 m in FY, 2019
USD

Revenue (Q1, 2020)

1.0m

Net income (Q1, 2020)

(4.1m)

EBIT (Q1, 2020)

(4.1m)

Market capitalization (29-Nov-2019)

16.6m

Closing stock price (29-Nov-2019)

2.1

Cash (31-Mar-2020)

7.1m

EV

9.6m
Vical's current market capitalization is $16.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

30.0m17.5m7.7m15.2m21.0m14.5m13.8m1.6m7.9m

Cost of goods sold

10.3m13.1m12.7m10.8m10.9m6.3m6.5m1.4m

Gross profit

19.8m4.5m(5.0m)4.4m10.0m8.2m7.3m186.0k

Gross profit Margin, %

66%25%(65%)29%48%57%53%11%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

818.0k26.6m11.5m1.6m2.2m1.6m1.5m1.5m2.4m4.5m3.4m4.9m4.2m5.0m4.6m4.1m2.6m3.2m3.4m3.2m716.0k735.0k47.0k1.2m1.0m

Cost of goods sold

2.6m2.3m2.5m2.9m3.9m3.7m3.9m3.9m1.5m3.7m2.3m2.9m2.4m1.3m2.8m1.2m993.0k1.3m1.6m1.8m1.4m

Gross profit

(1.8m)24.3m9.0m(1.4m)(1.7m)(2.1m)(2.4m)(2.4m)932.0k855.0k1.2m2.0m1.8m3.7m1.8m2.9m1.6m1.9m1.8m1.5m(720.0k)47.0k

Gross profit Margin, %

(219%)91%78%(87%)(77%)(136%)(167%)(153%)38%19%33%41%43%74%38%70%62%59%53%45%(101%)100%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

38.7m43.2m38.8m20.5m13.5m5.1m24.8m11.9m7.2m

Accounts Receivable

3.1m2.2m4.6m4.2m4.5m5.1m1.1m

Prepaid Expenses

6.2m

Inventories

Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

24.6m41.1m70.5m65.7m53.2m47.0m45.0m38.8m40.8m31.8m22.7m17.7m19.7m18.7m5.9m5.2m8.5m4.6m4.6m10.2m10.1m10.1m12.1m11.3m10.8m7.2m7.1m

Accounts Receivable

1.1m2.6m13.5m3.8m2.5m2.4m2.1m1.8m4.4m4.5m4.7m3.7m4.7m5.8m4.2m4.8m6.2m2.9m2.9m2.7m1.4m1.6m1.9m826.0k979.0k

Prepaid Expenses

5.0m5.8m

Current Assets

40.9m58.3m107.8m98.6m92.5m77.8m69.6m60.8m55.3m54.1m54.4m47.9m46.4m47.6m42.3m41.0m47.0m47.2m46.5m45.4m57.6m53.7m52.5m46.4m42.7m30.7m12.9m
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Vical Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Vical Online and Social Media Presence

Embed Graph

Vical News and Updates

Brickell Biotech Completes Merger with Vical

Newly Nasdaq-listed BBI focused on developing differentiated therapeutics for treatment of dermatologic disorders

Moore Kuehn, PLLC Encourages Vical Incorporated (VICL), ASV Holdings, Inc. (ASV), PCM, Inc. (PCMI), WageWorks, Inc. (WAGE), and Acacia Communications, Inc. (ACIA) Investors to Contact Firm

NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related to...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition

NEW YORK, June 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Vical Incorporated ("VICL" or the "Company") (NASDAQ: VICL) in connection with the proposed acquisition of the Company by...

Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives

SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that was initiated in the first quarter of 2018. The decision was based on the Company’s decision to conserve its cash resources wh…

Vical Reports Third Quarter 2018 Financial and Operational Results

SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2018. Net loss for the third quarter of 2018 was $1.5 million, or $0.07 per share, compared with a net loss of $3.1 million, or $0.27 per share, f…

Vical Reports Second Quarter 2018 Financial and Operational Results

SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended June 30, 2018. Net loss for the second quarter of 2018 was $4.9 million, or $0.22 per share, compared with a net loss of $3.3 million, or $0.30 per share, for t…
Show more

Vical Blogs

Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021- - -Initiated the Cardigan I study, the first of two U.S. pivotal Phase 3 clinical studies evaluating sofpironium bromide gel, 15% as a potential treatment for primary ax…

Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering

BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the pricing of…

AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.

Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in Japan IBARAKI CITY, Osaka and BOULDER, Colo., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AnGes, Inc. (“AnGes”), announced today a collaboration agreement with Brickell Biotec…

Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium bromide gel as early as the fourth quarter of 2020Brickell plans to initiate its U.S. pivotal Phase 3 program in …

Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020

BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will r…

Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update

Announces top-line results from 12-month, Phase 3, long-term safety study BOULDER, Colo., May 13, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for t…
Show more

Vical Frequently Asked Questions

  • When was Vical founded?

    Vical was founded in 1987.

  • How many employees does Vical have?

    Vical has 30 employees.

  • What is Vical revenue?

    Latest Vical annual revenue is $7.9 m.

  • What is Vical revenue per employee?

    Latest Vical revenue per employee is $263.9 k.

  • Who are Vical competitors?

    Competitors of Vical include Cure Genetics, Zyngenia and Onconetics Pharmaceuticals.

  • Where is Vical headquarters?

    Vical headquarters is located at 10390 Pacific Center Ct, San Diego.

  • Where are Vical offices?

    Vical has an office in San Diego.

  • How many offices does Vical have?

    Vical has 1 office.